Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05178862 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
A Phase 3 study, sponsored by Scynexis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
NCT05178862: Clinical Trial Phase 3 study, sponsored by Scynexis.
NCT05178862 is a Phase 3 study that was terminated before completion, run by Scynexis. The registered enrollment target is 68 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05178862, a Phase 3 study, was terminated before completion, sponsored by Scynexis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.
Primary Outcome
The number and percentage of subjects in each treatment group who are alive and deceased in the ITT population.
Interventions
- DRUG Fluconazole
- DRUG SCY-078
- DRUG Echinocandin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2025-12-16 |
| Phase | Phase 3 |
Why NCT05178862 stopped before completion
NCT05178862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Fluconazole is the first listed.
NCT05178862 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05178862 about?
NCT05178862 is a clinical study titled "A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole". This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.
What is the current status of trial NCT05178862?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2022-08-03. Estimated completion is 2025-12-16.
What interventions are being tested in trial NCT05178862?
The interventions under investigation include: Fluconazole (DRUG), SCY-078 (DRUG), Echinocandin (DRUG).
Who is sponsoring clinical trial NCT05178862?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05178862's enrollment target sits among peer trials
68 1796th of 2000 higher than 205 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI